Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor-Reference-Cited by-同舟云学术

Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor

Published:2015-05 Issue:4 Volume:29 Page:595-598
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

de Luis Daniel Antonio,Diaz Soto Gonzalo,Izaola Olatz,Romero Enrique

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference26 articles.

1. Effect of GLP-1 receptor variants on weight loss and comorbidities in obese patients under bariatric surgery;Barash,2012

2. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor;Bullock;Endocrinology,1996

3. Relation of the rs6923761 gene variant in glucagon-like peptide 1 receptor with weight, cardiovascular risk factor, and serum adipokine levels in obese female subjects;de Luis;Journal of Clinical Laboratory Analysis,2014

4. Evaluation of weight loss and adipocytokine levels after two hypocaloric diets with different macronutrient distribution in obese subjects with the rs6923761 gene variant of glucagon-like peptide 1 receptor;De Luis;Annals of Nutrition & Metabolism,2013

5. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2;de Luis;Journal of Investigative Medicine,2014

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers and Precision Medicine in Diabetes;Textbook of Diabetes;2024-01-12

2. Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus;Advances in Therapy;2024-01-04

3. Pharmacogenomics: The roles of genetic factors on treatment response and outcomes in diabetes;Internet of Things and Machine Learning for Type I and Type II Diabetes;2024

4. Precision medicine of obesity as an integral part of type 2 diabetes management – past, present, and future;The Lancet Diabetes & Endocrinology;2023-11

5. Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations;Diabetes, Metabolic Syndrome and Obesity;2023-11